Which act focuses on the use of narcotic drugs in addiction treatment programs?

The FDA Narcotic Regulations specifically address the use of narcotic drugs in addiction treatment programs. These regulations provide guidance and enforcement mechanisms to ensure that the use of such drugs in the treatment of substance use disorders meets safety, efficacy, and regulatory standards.

In addiction treatment, certain narcotic medications, such as methadone or buprenorphine, are permitted under specific conditions to assist with withdrawal symptoms and cravings. The FDA has established clear protocols for prescribing and dispensing these medications, which fall under the classifications and guidelines set forth in the regulations. These include requirements for certified treatment programs and regulations around the monitoring of patient care.

The other options—such as the Prescription Marketing Act, which regulates the distribution of prescription drug samples and marketing practices; the Durham-Humphrey Amendment, which categorized prescription versus over-the-counter medications; and the Orphan Drug Act, which incentivizes drug development for rare conditions—do not specifically focus on the use of narcotic drugs in addiction treatment programs. Hence, they do not encompass the regulatory framework that directly pertains to the treatment of addiction with narcotics.